Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
formoterol + hydrocortisone
- Development stage
- Preclinical
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Inhalation, Topical, Oral, Intravenous
01
Overview
A combination of formoterol, a long-acting beta-2 adrenergic agonist (LABA), and hydrocortisone, a glucocorticoid corticosteroid. Formoterol works by relaxing and opening air passages in the lungs by stimulating beta-2 receptors, while hydrocortisone provides anti-inflammatory effects. This combination may be used for respiratory conditions such as asthma and COPD, though it is not available as a fixed-dose combination product.
02
Targets
GR (Glucocorticoid receptor)ADRB2 (β2)
Beyond the preview
Go deeper on formoterol + hydrocortisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on formoterol + hydrocortisone.